- Home
- ACHV vs MSD Comparison
ACHV vs MSD Comparison
Compare ACHV & MSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACHV | MSD |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 146.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACHV | MSD |
|---|---|---|
| Price | $4.65 | $7.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | ★ 653.5K | 70.2K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.84 | $6.11 |
| 52 Week High | $5.78 | $7.46 |
Technical Indicators
Market Signals| Indicator | ACHV | MSD |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 53.86 |
| Support Level | $4.45 | $7.35 |
| Resistance Level | $5.19 | $7.41 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 58.97 | 84.21 |
Price Performance
Historical ComparisonAbout ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About MSD Morgan Stanley Emerging Markets Debt Fund Inc.
Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.